In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Pölcher, Martin ^a   Rudlowski, Christian ^a   Friedrichs, Nicolaus ^a,c   Mielich, Marieke ^a   Höller, Tobias ^b   Wolfgarten, Mathias ^a   Kübler, Kirsten ^a   Büttner, Reinhard ^a   Kuhn, Walther ^a   Braun, Michael ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CD31 ANTIGEN; CD34 ANTIGEN; DOCETAXEL; ENDOGLIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2-40; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; TAXOID;

ADJUVANT THERAPY; ADULT; AGED; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VASCULARIZATION; ADJUVANT CHEMOTHERAPY; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; GERMANY; KAPLAN MEIER METHOD; MICROVASCULATURE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TIME; VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MICROVESSELS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950648682     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-137     Document Type: Article

References (49)

1. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S161-192. 10.1016/S0020-7292(06)60033-7, 17161157.
2. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001, 92(10):2585-2591. 10.1002/1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO;2-#, 11745193.
3. Park TW, Kuhn WC. Neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther 2004, 4(4):639-647. 10.1586/14737140.4.4.639, 15270667.
4. Polcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, Hoss C, Leutner C, Braun M, Mobus V, et al. Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer - a prospective multicenter phase II trial (PRIMOVAR). Oncol Rep 2009, 22(3):605-613. 10.3892/or_00000479, 19639211.
5. Vergote IB, Tropé CG, Amant F, Kristensen GB, Sardi JE. EORTC-GCG/NCIC-CTG Randomised Trial Comparing Primary Debulking Surgery With Neoadjuvant Chemotherapy in Stage IIIC-IV Ovarian, Fallopian Tube and Peritoneal Cancer (OVCA). 12th Biennial Meeting, International Gynecological Cancer Society (IGCS): 2008; Bangkok 2008,
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186.
8. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995, 147(1):9-19. 1869874, 7541613.
9. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 1999, 5(3):587-591.
10. Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA, Radaelli U, Di Bacco A, Guglielmi RB, Bevilacqua P. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 1996, 69(3):205-211. 10.1002/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6, 8682589.
11. Labiche A, Elie N, Herlin P, Denoux Y, Crouet H, Heutte N, Joly F, Heron JF, Gauduchon P, Henry-Amar M. Prognostic significance of tumour vascularisation on survival of patients with advanced ovarian carcinoma. Histol Histopathol 2009, 24(4):425-435.
12. Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V, Taddei GL. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 2004, 14(5):815-823. 10.1111/j.1048-891X.2004.014514.x, 15361189.
13. Rossochacka-Rostalska B, Gisterek IJ, Suder E, Szelachowska JK, Matkowski RA, Lacko A, Kornafel JA. [Prognostic significance of microvessel density in ovarian cancer]. Wiad Lek 2007, 60(3-4):129-137.
14. Rubatt JM, Darcy KM, Hutson A, Bean SM, Havrilesky LJ, Grace LA, Berchuck A, Secord AA. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. Gynecol Oncol 2009, 112(3):469-474. 10.1016/j.ygyno.2008.11.030, 19135712.
15. Gadducci A, Ferrero A, Cosio S, Zola P, Viacava P, Dompe D, Fanelli G, Ravarino N, Motta M, Cristofani R, et al. Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res 2006, 26(5B):3925-3932.
16. Obermair A, Wasicky R, Kaider A, Preyer O, Losch A, Leodolter S, Kolbl H. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett 1999, 138(1-2):175-182. 10.1016/S0304-3835(99)00005-1, 10378790.
17. Ogawa S, Kaku T, Kobayashi H, Hirakawa T, Ohishi Y, Kinukawa N, Nakano H. Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett 2002, 176(1):111-118. 10.1016/S0304-3835(01)00754-6, 11790460.
18. Newman PJ. The role of PECAM-1 in vascular cell biology. Ann N Y Acad Sci 1994, 714:165-174. 10.1111/j.1749-6632.1994.tb12041.x, 8017765.
19. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003, 22(42):6557-6563. 10.1038/sj.onc.1206813, 14528280.
20. Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996, 87(1):1-13.
21. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002, 82(9):1255-1257.
22. Miller KD, Sweeney CJ, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001, 19(4):1195-1206.
23. Pölcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K. Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Advanced Ovarian Cancer - a Prospective Multicenter Phase 2 Trial (PRIMOVAR). Oncol Rep 2009, 22:605-613. 10.3892/or_00000479, 19639211.
24. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995, 36(2):169-180. 10.1007/BF00666038, 8534865.
25. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997, 57(1):81-86.
26. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 2002, 1(13):1191-1200.
27. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001, 61(8):3369-3372.
28. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003, 104(1):121-129. 10.1002/ijc.10907, 12532428.
29. Rudlowski C, Pickart AK, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S, Schroeder W. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 2006, 16(Suppl 1):183-189. 10.1111/j.1525-1438.2006.00307.x, 16515588.
30. Dome B, Timar J, Ladanyi A, Paku S, Renyi-Vamos F, Klepetko W, Lang G, Dome P, Bogos K, Tovari J. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. Crit Rev Oncol Hematol 2009, 69(2):108-124. 10.1016/j.critrevonc.2008.06.009, 18768327.
31. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 2004, 287(3):C572-579. 10.1152/ajpcell.00330.2003, 15308462.
32. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14(3):263-273. 10.1016/j.ccr.2008.08.001, 2565587, 18772115.
33. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003, 63(15):4342-4346.
34. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4(6):423-436. 10.1038/nrc1369, 15170445.
35. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26(1):76-82. 10.1200/JCO.2007.12.1939, 18165643.
36. Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007, 67(1):281-288. 10.1158/0008-5472.CAN-06-3282, 17210709.
37. Schirner M. Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev 2000, 19(1-2):67-73. 10.1023/A:1026500431505, 11191065.
38. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006, 6(11):835-845. 10.1038/nrc1971, 17036040.
39. Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001, 20(29):3806-3813. 10.1038/sj.onc.1204487, 11439344.
40. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, Braguer D. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005, 65(6):2433-2440. 10.1158/0008-5472.CAN-04-2624, 15781659.
41. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374(9698):1331-1338. 10.1016/S0140-6736(09)61157-0, 19767092.
42. Bolis G, Scarfone G, Polverino G, Raspagliesi F, Tateo S, Richiardi G, Melpignano M, Franchi M, Mangili G, Presti M, et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 2004, 22(4):686-690. 10.1200/JCO.2004.03.017, 14966092.
43. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000, 18(1):106-115.
44. Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, Wadler S, Spiegel G, Arbuck SG. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol 2003, 21(15):2843-2848. 10.1200/JCO.2003.10.082, 12807937.
45. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005, 5(7):516-525. 10.1038/nrc1650, 15965493.
46. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25(33):5165-5171. 10.1200/JCO.2007.11.5345, 18024863.
47. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25(33):5180-5186. 10.1200/JCO.2007.12.0782, 18024865.
48. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15(3):232-239. 10.1016/j.ccr.2009.01.021, 19249681.
49. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231. 10.1016/j.ccr.2009.01.027, 19249680.